合成分解剂 增强中外粉样蛋白β清除在阿尔茨海默氏症的疾病
Chunwei Tang1, Kun Han1, Xin Wen1
1State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shandong Key Laboratory of Targeted Drug Delivery and Advanced Pharmaceutics, School of Pharmaceutical Sciences, Department of Neurosurgery, Jinan Microecological Biomedicine Shandong Laboratory, NMPA Key Laboratory For Technology Research and Evaluation of Drug Products and Key Laboratory of Chemical Biology (Ministry of Education), Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Advanced materials (Deerfield Beach, Fla.)
|January 9, 2026
概括
这项研究引入了一种用于阿尔茨海默病 (AD) 的新疗法,该疗法使用由纳米粒子输送的合成粉样β分解剂. 这种方法分解有毒的Aβ聚合物,并增强巨细胞清除,逆转AD病理.
科学领域:
- 神经科学是一个神经科学.
- 生物技术是生物技术.
- 药理学 药理学是指药理学的学科.
背景情况:
- 致病性粉样蛋白-β (Aβ) 积累驱动阿尔茨海默病 (AD) 病理,神经元损伤和神经炎症.
- 微质和巨细胞的Aβ清除受损会加剧AD的进展.
研究的目的:
- 开发和评估一种用于AD的新型治疗策略,使用现场工程合成Aβ分解剂 (SAD).
- 研究通过基于DHA的脂质纳米颗粒 (DLNP) 传递的SAD的双重作用机制,以增强Aβ清除和减少神经炎症.
主要方法:
- 在基于DHA的神经保护性脂质纳米颗粒 (DLNP) 中封装的工程合成Aβ分解剂 (SAD).
- 在体外和体内研究中,使用DLNP递送的SAD来重编程外围巨细胞.
- 在小鼠模型中评估Aβ分解,巨细胞化,神经炎症和AD病理.
主要成果:
- DLNP成功地传递了SAD来重编程外围巨细胞,从而使大脑Aβ分解.
- 抑郁症治疗抑制了神经炎症病理,并增强了Aβ的巨细胞化.
- 在小鼠模型中,DLNP有效地降低了脑Aβ积累,并逆转了AD病理.
结论:
- 该SAD-DLNP平台通过直接分解Aβ和增强巨细胞介导清除,为AD提供双重作用的治疗方法.
- 这种中心-外围向策略显示了扭转AD病理的巨大潜力,突出了基于mRNA的in situ融合蛋白作为一个有前途的治疗途径.
相关概念视频
01:22Alzheimer's Disease: Treatment
806
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
806
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K